Gerd Ritter - Concepedia

Author

Gerd Ritter

Memorial Sloan Kettering Cancer Center

Also Known As

G Ritter, G. D. Ritter, G.D. Ritter, Gerd Ritter

Publications

Citations

H-Index

Concepts

All Affiliations

Memorial Sloan Kettering Cancer Center Ludwig Cancer Research Ludwig Cancer Research University of Alabama at Birmingham Alabama Department of Public Health

About

Gerd Ritter is an author at Memorial Sloan Kettering Cancer Center specializing in immunology, medicine, and cancer research.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	9	9	995
2	Cell Biology	6	6	773
3	Natural Sciences	2	2	240
4	Allergy	2	2	181
5	Biomolecular Engineering	2	2	65

Gerd Ritter

Publications

Citations

H-Index

Page 1

	Year	Citations
A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer. Andrew M. Scott, G. Wiseman, Sydney Welt, PubMed	2003	441
A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors Andrew M. Scott, Fook-Thean Lee, Niall C. Tebbutt, Proceedings of the National Academy of Sciences ImmunologyDermatologyImmunotherapyUnique EpitopeTumor Biology	2007	217
The human A33 antigen is a transmembrane glycoprotein and a novel member of the immunoglobulin superfamily Joan K. Heath, Sara J. White, Cameron N. Johnstone, Proceedings of the National Academy of Sciences Murine A33 MabImmunologyPathologyAntigen ProcessingTumor Biology	1997	190
A monoclonal antibody recognizing human cancers with amplification/overexpression of the human epidermal growth factor receptor Achim A. Jungbluth, Elisabeth Stockert, Hongyi Huang, Proceedings of the National Academy of Sciences ImmunologyPathologyImmunotherapyReactivity PatternCancer Biology	2003	173
The Rabbit Antibody Repertoire as a Novel Source for the Generation of Therapeutic Human Antibodies Christoph Rader, Gerd Ritter, Sheila Nathan, Journal of Biological Chemistry Therapeutic Human AntibodiesImmunocytochemical TechniqueImmunologyImmunodominancePathology	2000	128
Ny-ESO-1 expression and immunogenicity associated with transitional cell carcinoma: correlation with tumor grade. Takushi Kurashige, Yuji Noguchi, Takashi Saika, PubMed Ny-eso-1 ExpressionTumoral PathologyOncologyCancer ImmunosurveillanceTumor Grade	2001	123
Phase I clinical trial with fractionated radioimmunotherapy using 131I-labeled chimeric G250 in metastatic renal cancer. Chaitanya Divgi, Joseph A. O’Donoghue, Sydney Welt, PubMed	2004	103
<sup>124</sup>I-huA33 Antibody PET of Colorectal Cancer Jorge A. Carrasquillo, Neeta Pandit‐Taskar, Joseph A. O’Donoghue, Journal of Nuclear Medicine	2011	98
Phase I study of anticolon cancer humanized antibody A33. Sydney Welt, Gerd Ritter, Clarence Williams, PubMed	2003	90
Specific Targeting, Biodistribution, and Lack of Immunogenicity of Chimeric Anti-GD3 Monoclonal Antibody KM871 in Patients With Metastatic Melanoma: Results of a Phase I Trial Andrew M. Scott, Fook-Thean Lee, Wendie Hopkins, Journal of Clinical Oncology	2001	87

Page 1